Company Overview and News


Add AMGN
to your dashboard

Headline News

5 Big Biotech Stocks To Buy In 2018

17h investorplace
While most investors tend to think of biotech stocks as pure lotto tickets, the reality is the sector is much more nuanced than that. Sure, there are bootstrapped, clinical-stage biotech stocks with only one potential drug in their arsenal. These are the ones that live or die by the FDA and clinical trials. (133-0)

Best ETFs for 2018: The SPDR S&P Biotech ETF (XBI) Will Continue to Rock

2018-01-17 investorplace
This article is a part of InvestorPlace’s Best ETFs for 2018 contest. Johnson Research Group’s pick for the contest is the SPDR S&P Biotech (ETF) (NYSEARCA:XBI). (93-0)

Biotech Stock Roundup: Juno Surges on Acquisition Rumor, Concert Down on Patent News

2018-01-17 zacks
Acquisitions once again remained in focus this week with Celgene (CELG - Free Report) rumored to be in talks with Juno (JUNO - Free Report) regarding a possible deal. Recap of the Week’s Most Important Stories Juno Soars on Acquisition Rumors: Juno’s shares skyrocketed on reports that Celgene is interested in acquiring the immuno-oncology focused company. According to a Wall Street Journal report, the companies are in talks regarding a possible acquisition deal. (376-0)

Will Amgen (AMGN) Continue to Tread Growth Path This Year?

2018-01-16 zacks
Amgen, Inc.’s (AMGN - Free Report) stock was up 19% in 2017, which compared favorably with a gain of 2.8% recorded by the industry. (135-0)

Biotech Daily Digest For January 16th

2018-01-16 seekingalpha
Biotech is rising in 2018 but still lags other sectors that will see more direct impacts from the recently passed tax legislation. (685-1)

Novartis (NVS) Announces Acceptance of Humira BLA by the FDA

2018-01-16 zacks
Novartis AG (NVS - Free Report) generic arm, Sandoz announced that the FDA accepted its Biologics License Application (BLA) for the proposed biosimilar of AbbVie, Inc. (ABBV - Free Report) Humira. (205-0)

4 ETFs Set to Surge in Q4 Earnings

2018-01-15 zacks
The fourth-quarter earnings season is expected to be strong, with earnings growth likely to pick up and continue accelerating after dipping in the preceding quarter. The S&P 500 index is anticipated to see earnings growth of 9.2% and revenue growth of 7%. The market is also at record levels, scaling series of highs at the start of the year. The forecast compares favorably with Q3 earnings growth of 6. (190-1)

Week In Review: Hua Medicine To Raise $200 Million Through Fundings And IPO For Oral Diabetes Drug

2018-01-14 seekingalpha
Hua Medicine of Shanghai expects to spend $200 million over the next three years on its novel oral diabetes 2 treatment, dorzagliatin. The company will raise additional capital for the effort and then IPO, possibly in Hong Kong or the US. The funds will underwrite Phase III development of its GKA product and commercialization. Ultimately, Hua hopes dorzagliatin will generate annual revenues of $3 billion, a 15% slice of the China type 2 diabetes market, once the drug is approved. (147-0)

Ternium & Cruises Top 20 'Safer' Dividend Miller/Howard Strategic Dividend Index Winter Gains

2018-01-12 seekingalpha
Miller/Howard Strategic Dividend Index (SDI) selection criteria are: (1) Dividend yield; (2) Asset valuation; (3) Profitability; (4) Estimated growth of yield; (5) Momentum. (151-0)

The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex

2018-01-12 zacks
Chicago, IL – January 12, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Celgene, Inc. (CELG - Free Report) , Amgen, Inc. (AMGN - Free Report) , Exelixis, Inc. (EXEL - Free Report) , Alexion Pharmaceuticals, Inc. (344-0)

Merck's Keytruda on a Roll: Can it Retain the Spark in 2018?

2018-01-12 zacks
With the rise in demand for immuno-oncology drugs and their combinations, Merck & Co., Inc.’s (MRK - Free Report) anti-PD-1 therapy, Keytruda, is fast becoming the key top-line driver of the pharma giant. (77-0)

Jeff Sessions is Taking Some Steam Out of the Marijuana Stocks Rally

2018-01-11 investorplace
Australia earlier this month joined the growing list of nations that have legalized medical marijuana. And as more countries are added to the list — as well as a smaller number approving or decriminalizing recreational use — many investors see upside remaining in cannabis-related stocks despite a recent rally. (141-0)

Short Sellers Grow More Selective on Major Biotechs

2018-01-11 247wallst
The short interest data are out for the most recent settlement date, December 29. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside. The health care sector in general has rallied since Donald Trump won the presidency, but now that the fate of the ACA is uncertain, the health care rally is called into question. (287-0)

Can Biotech Keep Last Year's Momentum Alive in 2018?

2018-01-11 zacks
The year 2017 has been better than expected for the biotech sector. The NASDAQ Biotechnology index was up 18.7% in 2017. While drug pricing issue, competition and a slowdown in growth of key drugs are expected to remain a hangover in 2018 as well, approval of new drugs and strategic acquisitions by several big wigs in 2017 are likely to boost investors’ sentiments. Thus 2018 needless to say, holds promise for generating stellar returns. (224-0)

AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU

2018-01-11 zacks
AstraZeneca, plc (AZN - Free Report) announced that the European Commission (“EC”) has granted approval to its asthma disease candidate, benralizumab. It is approved as an add-on maintenance treatment for severe eosinophilic asthma in adult patients. It will be marketed by the trade name of Fasenra. (344-0)

CUSIP: 031162100